287 related articles for article (PubMed ID: 9034838)
1. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.
Diestelhorst M; Roters S; Krieglstein GK
Graefes Arch Clin Exp Ophthalmol; 1997 Jan; 235(1):20-6. PubMed ID: 9034838
[TBL] [Abstract][Full Text] [Related]
2. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
[TBL] [Abstract][Full Text] [Related]
4. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
[TBL] [Abstract][Full Text] [Related]
5. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
Camras CB
Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
[TBL] [Abstract][Full Text] [Related]
6. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
Watson P; Stjernschantz J
Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
[TBL] [Abstract][Full Text] [Related]
7. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
8. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
Alm A; Stjernschantz J
Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
[TBL] [Abstract][Full Text] [Related]
9. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
Nordmann JP; Söderström M; Rouland JF; Malecaze F
Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
12. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.
Friström B
Acta Ophthalmol Scand; 1996 Apr; 74(2):140-4. PubMed ID: 8739678
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma.
Drance SM; Crichton A; Mills RP
Am J Ophthalmol; 1998 May; 125(5):585-92. PubMed ID: 9625541
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
Chew PT; Aung T; Aquino MV; Rojanapongpun P;
Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
[TBL] [Abstract][Full Text] [Related]
16. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy.
Palmberg P; Kim EE; Kwok KK; Tressler CS;
Eur J Ophthalmol; 2010; 20(4):708-18. PubMed ID: 20099236
[TBL] [Abstract][Full Text] [Related]
17. Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension.
Harasymowycz P; Hutnik CM; Nicolela M; Stewart WC
Can J Ophthalmol; 2007 Feb; 42(1):75-81. PubMed ID: 17361245
[TBL] [Abstract][Full Text] [Related]
18. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
[TBL] [Abstract][Full Text] [Related]
20. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
Diestelhorst M
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
